Genmab Reports New Epcoritamab Data, 93% ORR in Elderly DLBCL Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 14 2026
0mins
Genmab announced new data from two studies evaluating epcoritamab. Results from the Phase 2 EPCORE DLBCL-3 study showed an overall response rate, ORR, of 67% and a complete response rate of 58% with epcoritamab monotherapy in elderly patients with newly diagnosed DLBCL. In the Phase 1b/2 EPCORE NHL-2 study, epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone demonstrated an ORR of 93% and a CR rate of 86% in elderly patients with newly diagnosed DLBCL.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 25.390
Low
26.00
Averages
38.50
High
48.00
Current: 25.390
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genmab Major Shareholder Announcement
- Major Shareholder Change: Under Section 30 of the Danish Capital Markets Act, Orbis Investment Management Limited reported controlling voting rights to 3,112,476 shares in Genmab A/S as of June 12, 2026, representing 4.99% of the share capital and voting rights, which may influence the company's governance structure and shareholder decisions.
- Shareholder Transparency: This announcement enhances transparency regarding Genmab's shareholder structure, as Orbis's stake approaches 5%, potentially prompting market interest in the company's future strategic direction, especially in light of its ongoing antibody drug development efforts.
- Company Background: Established in 1999 and headquartered in Copenhagen, Denmark, Genmab is dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, having secured approvals for eight antibody drugs, showcasing its strong capabilities in the biotechnology sector.
- Future Outlook: Genmab is advancing a robust late-stage clinical pipeline aimed at delivering transformative medicines to patients, and Orbis's investment may provide support for the company's future R&D and market expansion, enhancing its competitiveness in the global biopharmaceutical market.
See More
Genmab Reports Positive Clinical Trial Results for Epcoritamab
- Clinical Trial Results: Genmab's epcoritamab demonstrated promising efficacy in two clinical studies for elderly patients with newly diagnosed diffuse large B-cell lymphoma, achieving an overall response rate of 67% and a complete response rate of 58%, providing a new treatment option for those ineligible for anthracycline-based chemotherapy.
- Combination Therapy Efficacy: The EPCORE NHL-2 trial showed that combining epcoritamab with R-mini-CHOP resulted in an overall response rate of 93% and a complete response rate of 86%, along with sustained minimal residual disease negativity, indicating the potential of this combination therapy in treatment.
- Safety Profile Analysis: The safety profile of epcoritamab was consistent with expectations, with 71% of patients experiencing cytokine release syndrome and 18% reporting immune effector cell-associated neurotoxicity syndrome, highlighting the need for careful monitoring of these adverse effects in clinical applications.
- Academic Presentation: The results from both studies were presented at the 2026 European Hematology Association Congress, enhancing the academic recognition of epcoritamab in the lymphoma treatment field, which may facilitate subsequent market promotion and clinical application.
See More
Epcoritamab Shows Significant Efficacy in Elderly DLBCL Patients
- Monotherapy Efficacy: The EPCORE DLBCL-3 trial demonstrated that epcoritamab monotherapy achieved an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% in elderly patients with newly diagnosed DLBCL, highlighting its potential in a high-need population.
- Combination Therapy Success: In the EPCORE NHL-2 trial, the combination of epcoritamab with R-mini-CHOP yielded an impressive ORR of 93% and a CR rate of 86%, indicating superior tolerability and efficacy compared to traditional treatments in elderly patients.
- Durable Responses: The EPCORE DLBCL-3 study revealed that at 12 months, 67% of responses and 73% of complete responses were ongoing, suggesting long-term efficacy and safety of epcoritamab in elderly patients.
- Favorable Safety Profile: While 71% of patients experienced cytokine release syndrome (CRS), the overall safety profile was consistent with expectations, with no severe adverse events reported, demonstrating the acceptability of epcoritamab in elderly populations.
See More
New Data on Epcoritamab Combination Therapy for Lymphoma Released
- Clinical Trial Results: In a study of 481 patients, the combination of Epcoritamab and R2 demonstrated significant efficacy, particularly in patients with FLIPI scores of 0-2, achieving an overall response rate of 96.5% compared to 84.8% for R2 alone, indicating the combination's critical role in improving patient survival.
- Subgroup Analysis Findings: The subgroup analysis revealed that Epcoritamab + R2 exhibited consistent efficacy across various risk profiles, with hazard ratios for progression-free survival (PFS) consistently below 0.3 in both FLIPI 0-2 and 3-5 groups, highlighting the treatment's adaptability and effectiveness across diverse patient populations.
- Safety Assessment: Although patients receiving lower doses of lenalidomide experienced increased risks of neutropenia and infections, the safety profile of Epcoritamab + R2 remained manageable with no new safety signals identified, demonstrating the sustainability and safety of this combination therapy.
- Future Treatment Outlook: Genmab executives indicated that the combination of Epcoritamab and R2 is poised to transform the treatment landscape for relapsed or refractory follicular lymphoma, offering a highly effective and broadly accessible treatment option, thereby advancing clinical practice in this field.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
Genmab Major Shareholder Announcement
- Major Shareholder Change: As of May 8, 2026, Orbis Investment Management Limited controls 5.08% of Genmab A/S's voting rights through 3,166,357 shares, which may influence the company's governance structure and shareholder decisions.
- Company Background: Genmab is an international biotechnology company dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, showcasing over 25 years of R&D experience and strong market competitiveness.
- Product Pipeline: Genmab is advancing multiple late-stage clinical programs aimed at delivering transformative medicines to patients, which not only enhances the company's market position but also lays the groundwork for future revenue growth.
- Risk Factors Highlighted: The announcement includes forward-looking statements that emphasize various risks associated with clinical development and market acceptance, prompting investors to consider these uncertainties when assessing the company's long-term investment value.
See More
Genmab Major Shareholder Announcement
- Major Shareholder Change: Under Section 30 of the Danish Capital Markets Act, Orbis Investment Management Limited reported controlling voting rights to 3,112,476 shares in Genmab A/S as of June 12, 2026, representing 4.99% of the share capital and voting rights, which may influence the company's governance structure and shareholder decisions.
- Shareholder Transparency: This announcement enhances transparency regarding Genmab's shareholder structure, as Orbis's stake approaches 5%, potentially prompting market interest in the company's future strategic direction, especially in light of its ongoing antibody drug development efforts.
- Company Background: Established in 1999 and headquartered in Copenhagen, Denmark, Genmab is dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, having secured approvals for eight antibody drugs, showcasing its strong capabilities in the biotechnology sector.
- Future Outlook: Genmab is advancing a robust late-stage clinical pipeline aimed at delivering transformative medicines to patients, and Orbis's investment may provide support for the company's future R&D and market expansion, enhancing its competitiveness in the global biopharmaceutical market.
See More
Genmab Reports Positive Clinical Trial Results for Epcoritamab
- Clinical Trial Results: Genmab's epcoritamab demonstrated promising efficacy in two clinical studies for elderly patients with newly diagnosed diffuse large B-cell lymphoma, achieving an overall response rate of 67% and a complete response rate of 58%, providing a new treatment option for those ineligible for anthracycline-based chemotherapy.
- Combination Therapy Efficacy: The EPCORE NHL-2 trial showed that combining epcoritamab with R-mini-CHOP resulted in an overall response rate of 93% and a complete response rate of 86%, along with sustained minimal residual disease negativity, indicating the potential of this combination therapy in treatment.
- Safety Profile Analysis: The safety profile of epcoritamab was consistent with expectations, with 71% of patients experiencing cytokine release syndrome and 18% reporting immune effector cell-associated neurotoxicity syndrome, highlighting the need for careful monitoring of these adverse effects in clinical applications.
- Academic Presentation: The results from both studies were presented at the 2026 European Hematology Association Congress, enhancing the academic recognition of epcoritamab in the lymphoma treatment field, which may facilitate subsequent market promotion and clinical application.
See More
Epcoritamab Shows Significant Efficacy in Elderly DLBCL Patients
- Monotherapy Efficacy: The EPCORE DLBCL-3 trial demonstrated that epcoritamab monotherapy achieved an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% in elderly patients with newly diagnosed DLBCL, highlighting its potential in a high-need population.
- Combination Therapy Success: In the EPCORE NHL-2 trial, the combination of epcoritamab with R-mini-CHOP yielded an impressive ORR of 93% and a CR rate of 86%, indicating superior tolerability and efficacy compared to traditional treatments in elderly patients.
- Durable Responses: The EPCORE DLBCL-3 study revealed that at 12 months, 67% of responses and 73% of complete responses were ongoing, suggesting long-term efficacy and safety of epcoritamab in elderly patients.
- Favorable Safety Profile: While 71% of patients experienced cytokine release syndrome (CRS), the overall safety profile was consistent with expectations, with no severe adverse events reported, demonstrating the acceptability of epcoritamab in elderly populations.
See More
New Data on Epcoritamab Combination Therapy for Lymphoma Released
- Clinical Trial Results: In a study of 481 patients, the combination of Epcoritamab and R2 demonstrated significant efficacy, particularly in patients with FLIPI scores of 0-2, achieving an overall response rate of 96.5% compared to 84.8% for R2 alone, indicating the combination's critical role in improving patient survival.
- Subgroup Analysis Findings: The subgroup analysis revealed that Epcoritamab + R2 exhibited consistent efficacy across various risk profiles, with hazard ratios for progression-free survival (PFS) consistently below 0.3 in both FLIPI 0-2 and 3-5 groups, highlighting the treatment's adaptability and effectiveness across diverse patient populations.
- Safety Assessment: Although patients receiving lower doses of lenalidomide experienced increased risks of neutropenia and infections, the safety profile of Epcoritamab + R2 remained manageable with no new safety signals identified, demonstrating the sustainability and safety of this combination therapy.
- Future Treatment Outlook: Genmab executives indicated that the combination of Epcoritamab and R2 is poised to transform the treatment landscape for relapsed or refractory follicular lymphoma, offering a highly effective and broadly accessible treatment option, thereby advancing clinical practice in this field.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
Genmab Major Shareholder Announcement
- Major Shareholder Change: As of May 8, 2026, Orbis Investment Management Limited controls 5.08% of Genmab A/S's voting rights through 3,166,357 shares, which may influence the company's governance structure and shareholder decisions.
- Company Background: Genmab is an international biotechnology company dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, showcasing over 25 years of R&D experience and strong market competitiveness.
- Product Pipeline: Genmab is advancing multiple late-stage clinical programs aimed at delivering transformative medicines to patients, which not only enhances the company's market position but also lays the groundwork for future revenue growth.
- Risk Factors Highlighted: The announcement includes forward-looking statements that emphasize various risks associated with clinical development and market acceptance, prompting investors to consider these uncertainties when assessing the company's long-term investment value.
See More
